Bank of New York Mellon Corp Cuts Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bank of New York Mellon Corp decreased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 3.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 372,507 shares of the company's stock after selling 12,337 shares during the quarter. Bank of New York Mellon Corp owned about 0.75% of Prestige Consumer Healthcare worth $32,024,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Proficio Capital Partners LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter worth approximately $1,689,000. PNC Financial Services Group Inc. raised its holdings in Prestige Consumer Healthcare by 5.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,276 shares of the company's stock valued at $412,000 after buying an additional 296 shares during the period. Amundi boosted its stake in Prestige Consumer Healthcare by 187.4% during the fourth quarter. Amundi now owns 25,669 shares of the company's stock worth $1,909,000 after buying an additional 16,737 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Prestige Consumer Healthcare by 7.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,053 shares of the company's stock valued at $863,000 after acquiring an additional 731 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Prestige Consumer Healthcare by 89.5% in the fourth quarter. HighTower Advisors LLC now owns 31,666 shares of the company's stock valued at $2,473,000 after acquiring an additional 14,958 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.6%

Shares of PBH stock traded down $0.49 on Thursday, hitting $74.69. 201,898 shares of the stock traded hands, compared to its average volume of 313,744. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.82 and a current ratio of 4.20. The firm's 50-day moving average price is $83.39 and its two-hundred day moving average price is $82.29. Prestige Consumer Healthcare Inc. has a twelve month low of $64.94 and a twelve month high of $90.04. The stock has a market capitalization of $3.69 billion, a PE ratio of 17.40, a PEG ratio of 2.26 and a beta of 0.43.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts' consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.87% and a net margin of 18.86%. The business had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. During the same period in the prior year, the business posted $1.02 EPS. The company's revenue was up 7.0% compared to the same quarter last year. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Ratings Changes

PBH has been the subject of several recent analyst reports. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.